---
title: "Clinical Feed — Source-Verified Medical Research & Clinical Intelligence"
canonical_url: "https://medichelpline.com/clinical-feed"
content_type: "clinical_feed_hub"
total_articles: 30
specialties_count: 22
generated_at: "2026-08-29T14:26:53.080Z"
license: "CC-BY-NC-4.0 / Informational Use"
---

# Clinical Feed — Source-Verified Medical Research & Journal Intelligence

## Executive Overview
MedicHelpline Clinical Feed continuously aggregates, normalizes, and synthesizes peer-reviewed medical research, clinical trials, regulatory bulletins, and journal articles across **22 medical specialties**.

## Browse by Specialty (.md Streams)
- [**Cardiology**](https://medichelpline.com/clinical-feed/cardiology.md) — Heart failure, interventional cardiology, lipid science, and cardiorenal updates.
- [**Critical Care**](https://medichelpline.com/clinical-feed/critical-care.md) — ICU protocols, sepsis pathways, ventilation, and emergency updates.
- [**Infectious Disease**](https://medichelpline.com/clinical-feed/infectious-disease.md) — Antimicrobial resistance, vaccines, outbreak tracking, and virology.
- [**Oncology**](https://medichelpline.com/clinical-feed/oncology.md) — Targeted therapies, immunotherapy trials, surgical oncology, and biomarkers.
- [**Neurology**](https://medichelpline.com/clinical-feed/neurology.md) — Neurodegenerative disease, stroke management, epilepsy, and neuroimaging.
- [**Pharmacology**](https://medichelpline.com/clinical-feed/pharmacology.md) — Drug mechanism, phase trials, pharmacokinetics, and interaction science.
- [**Research Highlights**](https://medichelpline.com/clinical-feed/research-highlights.md) — Cross-specialty breakthroughs, meta-analyses, and high-impact publications.
- [**Dentistry**](https://medichelpline.com/clinical-feed/dentistry.md) — Oral medicine, maxillofacial surgery, periodontology, and restorative dental science.
- [**Public Health**](https://medichelpline.com/clinical-feed/public-health.md) — Epidemiology, health policy, vaccination coverage, and prevention guidelines.
- [**Regulatory & FDA**](https://medichelpline.com/clinical-feed/regulatory.md) — FDA approvals, safety alerts, black box warnings, and guideline changes.
- [**Research & Trials**](https://medichelpline.com/clinical-feed/research.md) — Clinical trial protocols, preliminary data, methodology, and translational research.
- [**Clinical Practice**](https://medichelpline.com/clinical-feed/clinical-practice.md) — Point-of-care guidelines, diagnostic algorithms, and clinical case studies.
- [**General Medicine**](https://medichelpline.com/clinical-feed/general-medicine.md) — Primary care, internal medicine, preventive health, and multi-system care.
- [**Endocrinology**](https://medichelpline.com/clinical-feed/endocrinology.md) — Diabetes management, thyroid disorders, metabolic health, and hormonal therapy.
- [**Gastroenterology**](https://medichelpline.com/clinical-feed/gastroenterology.md) — IBD, hepatology, endoscopy, microbiome research, and GI oncology.
- [**Pulmonology**](https://medichelpline.com/clinical-feed/pulmonology.md) — COPD, asthma, interstitial lung disease, and respiratory critical care.
- [**Pediatrics**](https://medichelpline.com/clinical-feed/pediatrics.md) — Neonatology, pediatric development, adolescent medicine, and childhood diseases.
- [**Dermatology**](https://medichelpline.com/clinical-feed/dermatology.md) — Biologics for psoriasis, melanoma diagnosis, autoimmune skin conditions.
- [**Psychiatry**](https://medichelpline.com/clinical-feed/psychiatry.md) — Psychopharmacology, mood disorders, neurostimulation, and mental health.
- [**Nephrology**](https://medichelpline.com/clinical-feed/nephrology.md) — CKD progression, dialysis technologies, electrolyte balance, and renal transplant.
- [**Rheumatology**](https://medichelpline.com/clinical-feed/rheumatology.md) — Autoimmune diseases, arthritis therapies, lupus, and biologic treatments.
- [**Hematology**](https://medichelpline.com/clinical-feed/hematology.md) — Coagulation disorders, leukemia, lymphoma, anemia, and cellular therapies.

## Latest Clinical Research Publications
### 1. [Dual antithrombotic therapy with potent antiplatelet inhibitors in AF and ACS — randomized trial](https://medichelpline.com/clinical-feed/nature-0-dual-antithrombotic-therapy-using-potent-antiplatelet-inhibitors-in-atrial.md)
- **Source:** Nature Medicine | **Specialty:** [Cardiology](https://medichelpline.com/clinical-feed/cardiology.md) | **Published:** 2026-08-29
- **Read Full Markdown:** [Dual antithrombotic therapy with potent antiplatelet inhibitors in AF and ACS — randomized trial](https://medichelpline.com/clinical-feed/nature-0-dual-antithrombotic-therapy-using-potent-antiplatelet-inhibitors-in-atrial.md)

> **Executive GIST:** - The article reports a randomized controlled trial titled “Dual antithrombotic therapy using potent antiplatelet inhibitors in atrial fibrillation and acute coronary syndrome.” - The study was published in Nature Medicine on 29 August 2026 and lists many contributing authors. - The article frames the clinical problem: choosing an optimal antithrombotic regimen for patients with **atrial fibrillation (AF)** who also present with **acute coronary syndrome (ACS)** is challenging. - Existing randomized trials previously showed that **dual antithrombotic therapy (DAT)** — a **direct oral anticoagulant (DOAC)** plus a **P2Y12 inhibitor** — reduces **bleeding** compared with traditional **triple therapy** that included **vitamin K antagonists (VKAs)**. - Subsequent meta-analyses cited in the article have raised concern that DAT may be associated with a higher rate of **ischemic events** in some settings. - The provided source text contains only the article metadata and the opening of the Abstract; the remainder of the Abstract, full methods, results, and conclusions were not included in the supplied text and therefore are not reported here. - Where trial design, participant numbers, specific interventions, endpoints, statistical findings, safety outcomes, and authors' conclusions would normally appear, those details were not reported in the source text provided. - Readers are advised to consult the full Nature Medicine article or the PDF linked in the source for complete trial methods, outcome data, and authors' interpretation.

### 2. [Journalists Discuss Measles, Vaccination Rates, Food Recalls, Medicaid AI, and the ACA Ahead of Mi](https://medichelpline.com/clinical-feed/kff-health-news-0-with-midterms-looming-journalists-consider-measles-food-recalls-and-obamacare.md)
- **Source:** KFF Health News | **Specialty:** [General](https://medichelpline.com/clinical-feed/general.md) | **Published:** 2026-08-29
- **Read Full Markdown:** [Journalists Discuss Measles, Vaccination Rates, Food Recalls, Medicaid AI, and the ACA Ahead of Mi](https://medichelpline.com/clinical-feed/kff-health-news-0-with-midterms-looming-journalists-consider-measles-food-recalls-and-obamacare.md)

> **Executive GIST:** - KFF Health News journalists made multiple media appearances the week of Aug. 21–26, 2026 to discuss public health stories relevant to the upcoming midterm elections. - Céline Gounder, KFF Health News’ editor-at-large for public health, spoke on CBS News 24/7 programs about **measles**, recent fatal measles cases, vaccine issues and summer food recalls, and she fact-checked comments by CMS Administrator Mehmet Oz on **vaccines** and drug prices. - Julie Rovner, KFF Health News chief Washington correspondent, discussed kindergarten vaccination rates on WNYC’s The Brian Lehrer Show. - Mark Kreidler, a KFF Health News contributor, talked about the use of **artificial intelligence** to assist with **Medicaid** reenrollment on KVPR’s Central Valley Daily and authored a related KFF Health News story. - Julie Appleby, senior correspondent, discussed the state of the **Affordable Care Act** on Vox’s Today, Explained podcast. - Briah Lumpkins, KFF Health News Georgia correspondent, addressed the role of healthcare policy in voters’ priorities for upcoming elections on WUGA’s The Georgia Health Report. - The item links to recordings or pages for each appearance and a related KFF Health News article about AI in Medicaid; it situates these reports as part of KFF Health News On Air coverage ahead of midterms. - The coverage touches on public-health matters (vaccination rates and measles), food safety (recalls), health policy (ACA, Medicare/Medicaid topics, drug prices), and technology in enrollment, but specific data points beyond program appearances were not reported in the source.

### 3. [Pacibekitug, an IL-6 antibody, lowered inflammation in Phase 2 TRANQUILITY — implications for hear](https://medichelpline.com/clinical-feed/stat-news-0-stat-a-novartis-drug-cut-inflammation-can-it-improve-heart-outcomes.md)
- **Source:** STAT News | **Specialty:** [Cardiology](https://medichelpline.com/clinical-feed/cardiology.md) | **Published:** 2026-08-29
- **Read Full Markdown:** [Pacibekitug, an IL-6 antibody, lowered inflammation in Phase 2 TRANQUILITY — implications for hear](https://medichelpline.com/clinical-feed/stat-news-0-stat-a-novartis-drug-cut-inflammation-can-it-improve-heart-outcomes.md)

> **Executive GIST:** - A newly acquired Novartis antibody, **pacibekitug**, produced sustained reductions in **inflammation** biomarkers in a midstage (Phase 2) study called TRANQUILITY, according to results presented at the European Society of Cardiology annual meeting in Munich. - Investigators reported a **dose-dependent** fall in biomarker levels on certain measures, indicating higher doses produced greater reductions and suggesting target engagement. - Pacibekitug is an antibody directed against **IL-6 (interleukin-6)**, a cytokine involved in immune regulation and a shared inflammatory driver implicated in cardiovascular risk. - The reported data come from a midstage trial; the article notes the results were presented publicly but is behind a STAT+ paywall, and many trial details were not provided in the accessible portion of the source. - The company and external experts are awaiting Novartis’s plans for advancing the drug toward potential **cardiovascular** indications; the article emphasizes uncertainty about whether inflammation lowering will translate into improved heart outcomes. - The source reported the study was presented at the ESC meeting in Munich and characterized the reductions as sustained, but did not provide specific biomarker names, numerical effect sizes, patient numbers, safety data, or cardiovascular event results in the accessible text. - Overall, the report frames pacibekitug as biologically active against a key inflammatory pathway but highlights that proof of clinical benefit for heart disease remains unreported and is pending further development and data disclosure.

### 4. [Airway Diseases in Poultry Industry Workers: Occupational Exposures and Clinical Implications](https://medichelpline.com/clinical-feed/pubmed-42665724.md)
- **Source:** PubMed / NCBI | **Specialty:** [Critical Care](https://medichelpline.com/clinical-feed/critical-care.md) | **Published:** 2026-08-29 | DOI: [10.1007/s11882-026-01289-y](https://doi.org/10.1007%2Fs11882-026-01289-y)
- **Read Full Markdown:** [Airway Diseases in Poultry Industry Workers: Occupational Exposures and Clinical Implications](https://medichelpline.com/clinical-feed/pubmed-42665724.md)

> **Executive GIST:** - The global expansion and commercialization of the **poultry industry** has increased demand and workforce exposure to complex airborne hazards in poultry production settings. - Poultry workers are exposed to a mixture of organic and inorganic compounds, fumes, microorganisms, and particulate matter present in barns and processing facilities. - Documented airborne contaminants include **feathers**, mites, **feed dust**, **molds**, **ammonia**, and bacterial **endotoxins**, all of which have been linked to airway inflammation and hypersensitivity. - These exposures contribute to a rising burden of **occupational asthma** and chronic obstructive pulmonary disease (**COPD**) among poultry workers, with symptoms ranging from wheeze and chest tightness to chronic cough and dyspnea. - If unrecognized or unmanaged, symptomatic workers can progress to clinically significant and chronic respiratory conditions. - Recent efforts emphasize workplace best practices, pollution reduction strategies, and active research into interventions to minimize exposure-related disease. - Healthcare providers play a central role through early identification of at-risk workers, thorough occupational history-taking, targeted diagnostic evaluation, and individualized management to prevent progression and improve outcomes. - The review highlights the need for ongoing surveillance, preventive measures, education of workers and clinicians, and implementation of targeted workplace controls to protect respiratory health in this vulnerable occupational group. - The article is a review published in Curr Allergy Asthma Rep (2026) by Margaret Hutson and Kristina L Bailey (PMID 42665724, DOI 10.1007/s11882-026-01289-y) and declares no competing interests. - MeSH indexing emphasizes occupational air pollutants, occupational diseases (epidemiology and etiology), and respiratory tract disease associations with poultry exposures.

### 5. [TET1-driven demethylation of MRPS17 promotes LUAD via the PI3K-AKT-mTOR pathway](https://medichelpline.com/clinical-feed/pubmed-42665721.md)
- **Source:** PubMed / NCBI | **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md) | **Published:** 2026-08-29 | DOI: [10.1007/s10735-026-10862-8](https://doi.org/10.1007%2Fs10735-026-10862-8)
- **Read Full Markdown:** [TET1-driven demethylation of MRPS17 promotes LUAD via the PI3K-AKT-mTOR pathway](https://medichelpline.com/clinical-feed/pubmed-42665721.md)

> **Executive GIST:** - The study investigates the role of mitochondrial ribosomal protein S17 (**MRPS17**) in lung adenocarcinoma (**LUAD**) and its regulation by the DNA demethylase **TET1**. - Analysis of LUAD tissues showed **MRPS17** upregulation and an association with worse prognosis in patients. - Functional experiments in LUAD cell lines demonstrated that **MRPS17** overexpression enhances proliferation, migration, and invasion, while **MRPS17** knockdown increases apoptosis and reduces tumorigenic properties in vitro and in vivo. - Epigenetic assays identified **TET1** as a regulator that demethylates the **MRPS17** promoter, increasing MRPS17 transcription. - Activation of the **PI3K-AKT-mTOR** signaling cascade was observed downstream of MRPS17, implicating this pathway in MRPS17-driven tumor aggressiveness. - The authors propose a mechanistic axis: **TET1**-mediated promoter demethylation → increased **MRPS17** expression → activation of **PI3K-AKT-mTOR** → enhanced LUAD progression. - The study positions **MRPS17** as a potential prognostic biomarker and a candidate therapeutic target, and it highlights epigenetic modulation of MRPS17 as a possible intervention point. - Details such as cohort size, specific experimental conditions, quantitative effect sizes, and some methodological specifics were not reported in the PubMed abstract and would require consulting the full article for verification. - Ethical approvals for retrospective human data use and animal experiments were obtained from Harbin Medical University Cancer Hospital; informed consent was waived for retrospective samples and data were anonymized. - Authors declared no conflicts of interest.

### 6. [Tiletamine‑zolazepam (Zoletil 50) inhalation: neuropsychiatric and multisystem toxicity with two‑y](https://medichelpline.com/clinical-feed/pubmed-42665695.md)
- **Source:** PubMed / NCBI | **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md) | **Published:** 2026-08-29 | DOI: [10.1007/s00415-026-14098-0](https://doi.org/10.1007%2Fs00415-026-14098-0)
- **Read Full Markdown:** [Tiletamine‑zolazepam (Zoletil 50) inhalation: neuropsychiatric and multisystem toxicity with two‑y](https://medichelpline.com/clinical-feed/pubmed-42665695.md)

> **Executive GIST:** - This retrospective case series examined 36 patients with recreational inhalation exposure to **tiletamine‑zolazepam (Zoletil 50)** presenting to a single institution. - All patients (100%) had **postural tremor**; 61% had sustained high‑amplitude tremor early after admission. - Cerebellar **ataxia** occurred in 83% and **visual disturbance** in 56%; 44% experienced concomitant hallucinations. - Parkinsonian features (bradykinesia and rigidity) were present in 11% of patients. - Systemic laboratory abnormalities included elevated transaminases in 53% and hypokalemia in 44%. - Two patients died in hospital from cardiorespiratory failure; a third death occurred during follow‑up after repeated relapses. - Of 34 discharged patients, 59% relapsed (20 patients), and 17 relapsed within the first month, indicating **early and common relapse**. - At two years, 11 of 33 survivors had persistent deficits: subjective memory decline (7), visual impairment (6), and bradykinesia requiring levodopa (2). - The authors emphasize that standard toxicology screens do not detect tiletamine‑zolazepam and recommend clinicians consider this exposure in young patients with unexplained tremor, ataxia, or perceptual disturbances. - The study calls for prospective controlled research to confirm causation and fully define the toxicity spectrum.

### 7. [Fatal Waterhouse–Friderichsen Syndrome at Autopsy: Systematic Review and Forensic Diagnostic Frame](https://medichelpline.com/clinical-feed/pubmed-42665693.md)
- **Source:** PubMed / NCBI | **Specialty:** [Critical Care](https://medichelpline.com/clinical-feed/critical-care.md) | **Published:** 2026-08-29 | DOI: [10.1007/s00414-026-03978-9](https://doi.org/10.1007%2Fs00414-026-03978-9)
- **Read Full Markdown:** [Fatal Waterhouse–Friderichsen Syndrome at Autopsy: Systematic Review and Forensic Diagnostic Frame](https://medichelpline.com/clinical-feed/pubmed-42665693.md)

> **Executive GIST:** - Waterhouse–Friderichsen syndrome (WFS) is a fulminant septic condition defined by **bilateral adrenal hemorrhage** and rapid clinical decline; although classically linked to meningococcal infection, fatal WFS occurs with multiple infectious causes and heterogeneous clinical contexts. - The authors performed a systematic review following **PRISMA** guidelines, searching PubMed/MEDLINE, Scopus, and Google Scholar through 21 February 2026 to identify autopsy-confirmed fatal cases consistent with WFS. - Inclusion required human fatal cases with bilateral adrenal hemorrhage documented at autopsy and sufficient pathological and/or microbiological data; 65 studies reporting 86 individual fatal cases met criteria. - Across cases, bilateral adrenal hemorrhage was consistently part of a wider systemic septic pattern including multiorgan congestion, hemorrhagic manifestations, and variable changes related to **disseminated intravascular coagulation (DIC)**. - Histopathological appearances and microbiological results were heterogeneous; frequent discrepancies occurred between culture-based and molecular microbiology, and post-mortem microbiology had recurrent diagnostic limitations. - The authors argue WFS should be interpreted as a recurrent **forensic-pathological pattern** rather than a single morphological diagnosis, given variable etiologies and pathological presentations. - Based on recurring findings, the review developed practical forensic frameworks to support autopsy interpretation, microbiological sampling, and differential diagnosis in sudden septic deaths. - The proposed approach emphasizes integration of macroscopic morphology, histopathology, microbiology, and circumstantial data to improve consistency and reproducibility in medico-legal evaluations. - The review highlights the impact of heterogeneous case-level reporting on synthesis and the need to acknowledge limitations inherent to post-mortem investigations when attributing cause of death in suspected WFS cases.

### 8. [Safety and Long-Term Outcomes of Surgical Treatment for Pediatric Necrotizing Pneumonia](https://medichelpline.com/clinical-feed/pubmed-42665678.md)
- **Source:** PubMed / NCBI | **Specialty:** [Pediatrics](https://medichelpline.com/clinical-feed/pediatrics.md) | **Published:** 2026-08-29 | DOI: [10.1007/s00431-026-07365-9](https://doi.org/10.1007%2Fs00431-026-07365-9)
- **Read Full Markdown:** [Safety and Long-Term Outcomes of Surgical Treatment for Pediatric Necrotizing Pneumonia](https://medichelpline.com/clinical-feed/pubmed-42665678.md)

> **Executive GIST:** - This retrospective cohort studied 398 children diagnosed with **necrotizing pneumonia (NP)** from January 2017 to June 2025; 42 (10.55%) underwent surgical intervention after failed medical therapy. - Pathogens were identified in 95.2% of surgically treated cases; **Mycoplasma pneumoniae** was the most frequent single pathogen (52.50%). - Preoperative complications were present in 83.33% of children who had surgery. - Operative metrics for the surgical cohort: mean operative time 140.71 ± 49.84 minutes; mean intraoperative blood loss 119.79 ± 49.97 mL; mean chest tube duration 7.83 ± 3.05 days; mean postoperative hospital stay 14.74 ± 3.53 days. - Patients who underwent parenchymal resection had significantly longer operative time (P 0.05). - Five postoperative pulmonary adverse events occurred; all resolved with conservative management and there were no surgical-site mortalities. - Median follow-up was 64.4 months (range 5–101 months); during follow-up there were no recurrences or deaths reported. - Authors conclude that timely and individualized surgical intervention, including **lung resection** when indicated, is safe and linked to excellent long-term recovery in pediatric NP. - Ethics approval and written informed consent were obtained; authors declared no competing interests.

### 9. [Systematic reviews and adolescent transgender health: evidence, gaps, and policy implications](https://medichelpline.com/clinical-feed/pubmed-42660154.md)
- **Source:** PubMed / NCBI | **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md) | **Published:** 2026-08-29 | DOI: [10.1016/S0140-6736(26)00788-9](https://doi.org/10.1016%2FS0140-6736(26)00788-9)
- **Read Full Markdown:** [Systematic reviews and adolescent transgender health: evidence, gaps, and policy implications](https://medichelpline.com/clinical-feed/pubmed-42660154.md)

> **Executive GIST:** - The article is a Viewpoint in Lancet examining how **systematic reviews** have been used in literature and policy concerning medical care for transgender adolescents (puberty start to age 18). - Since 2017, 13 reviews (seven since 2023) have summarized studies of **puberty suppression** and **gender-affirming hormone therapy** on psychosocial, cognitive, and physical outcomes in transgender, gender diverse, and non-binary adolescents. - Systematic reviews are regarded as high-quality evidence in evidence-based medicine; thus their conclusions significantly affect health-care guidance, government policy, and public debate. - The authors review conclusions from these systematic reviews about efficacy and safety of interventions and highlight concerns about misuse of review findings to shape treatment options and care pathways. - The Viewpoint stresses that clinical guideline development should integrate all three pillars of evidence-based medicine: empirical evidence, clinical expertise, and patient values, and that experts in the field should evaluate these facets. - The article documents author affiliations with the Amsterdam University Medical Center and notes funding and other declarations of interest for both authors. - MeSH indexing covers topics including Adolescent, Evidence-Based Medicine, Gender-Affirming Care, Puberty Suppression, Transgender Persons, Health Policy, and Politics, reflecting the clinical and policy focus of the piece. - The authors caution that selective or inappropriate use of systematic reviews can influence care pathways and broader societal debates, implying the need for careful appraisal and balanced guideline processes. - Specific methodological details of the included systematic reviews, numeric outcomes, and granular study-level results are not reported in the abstract and therefore are not provided in this Viewpoint summary.

### 10. [Rezpegaldesleukin (REZOLVE-AD) phase 2b: 16-week induction study of moderate-to-severe atopic derm](https://medichelpline.com/clinical-feed/pubmed-42628554.md)
- **Source:** PubMed / NCBI | **Specialty:** [General](https://medichelpline.com/clinical-feed/general.md) | **Published:** 2026-08-29 | DOI: [10.1016/S0140-6736(26)01143-8](https://doi.org/10.1016%2FS0140-6736(26)01143-8)
- **Read Full Markdown:** [Rezpegaldesleukin (REZOLVE-AD) phase 2b: 16-week induction study of moderate-to-severe atopic derm](https://medichelpline.com/clinical-feed/pubmed-42628554.md)

> **Executive GIST:** - The REZOLVE-AD study evaluated **rezpegaldesleukin** in adults with moderate-to-severe **atopic dermatitis** during a 16-week induction period. - The trial was an international, randomized, double-blind, placebo-controlled **phase 2b** study. - The final results from the 16-week induction period were published in Lancet (Aug 29, 2026; Epub Aug 22, 2026). - The article lists a large, multi-country investigator group and numerous collaborating sites and investigators, reflecting a global study network. - The publication includes many academic and clinical authors and contributors from Nektar Therapeutics and multiple dermatology centers. - The PubMed entry provides bibliographic details (DOI: 10.1016/S0140-6736(26)01143-8) and a link to Elsevier Science full text options. - The abstract and PubMed record visible here describe study design and authorship but do not include outcome data, efficacy, or safety results in the provided excerpt. - Details such as participant numbers, baseline characteristics, primary and secondary endpoint results, statistical outcomes, and safety findings were not reported in the source excerpt available here. - Readers should consult the full Lancet article or publisher site for complete efficacy and safety data and for full methods, statistical analysis, and supplementary materials.

### 11. [Belzutifan plus lenvatinib vs cabozantinib in previously treated advanced renal cell carcinoma — L](https://medichelpline.com/clinical-feed/pubmed-42586114.md)
- **Source:** PubMed / NCBI | **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md) | **Published:** 2026-08-29 | DOI: [10.1016/S0140-6736(26)01089-5](https://doi.org/10.1016%2FS0140-6736(26)01089-5)
- **Read Full Markdown:** [Belzutifan plus lenvatinib vs cabozantinib in previously treated advanced renal cell carcinoma — L](https://medichelpline.com/clinical-feed/pubmed-42586114.md)

> **Executive GIST:** - The source article reports the LITESPARK-011 clinical trial, a randomised, open-label, controlled **phase 3** study comparing **belzutifan plus lenvatinib** versus **cabozantinib** in patients with previously treated advanced **renal cell carcinoma**. - Publication metadata: published in Lancet (Aug 29, 2026; volume 408, pages 808–820), DOI 10.1016/S0140-6736(26)01089-5; electronic publication date Aug 12, 2026. - The trial is identified as LITESPARK-011 and lists a large, international group of investigators and collaborators from North America, Europe, Asia, South America, and Australia. - Lead authors include Robert J Motzer and many coauthors representing multiple academic centres and Merck & Co contributors; numerous trial investigators and collaborators are named. - The source text provided contains title, author list, affiliations, collaborator names, journal citation, and publication details but does not include the trial abstract, numerical results, primary or secondary endpoint data, safety outcomes, statistical analyses, or detailed methods in the displayed portion. - Key trial characteristics explicitly reported in the source: randomized, open-label, controlled design; phase 3 status; patient population described broadly as those with previously treated advanced renal cell carcinoma. - The full-text link to Elsevier Science (Lancet) is present, but the provided source excerpt does not include efficacy, safety, or subgroup findings. - Because outcome data, eligibility criteria, sample size, dosing regimens, and statistical results are not included in the supplied source text, those details are not reported here and cannot be inferred. - Readers are referred to the full Lancet article for complete methods, results, safety, and interpretation; the PubMed entry lists extensive collaborators and institutional affiliations but omits the trial content in the excerpt provided.

### 12. [Once-weekly islatravir‑lenacapavir single‑tablet switch is non‑inferior to daily ART at 48 weeks i](https://medichelpline.com/clinical-feed/pubmed-42586113.md)
- **Source:** PubMed / NCBI | **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md) | **Published:** 2026-08-29 | DOI: [10.1016/S0140-6736(26)01442-X](https://doi.org/10.1016%2FS0140-6736(26)01442-X)
- **Read Full Markdown:** [Once-weekly islatravir‑lenacapavir single‑tablet switch is non‑inferior to daily ART at 48 weeks i](https://medichelpline.com/clinical-feed/pubmed-42586113.md)

> **Executive GIST:** - The phase 3 ISLEND-2 trial evaluated switching virologically suppressed adults with **HIV‑1** from daily oral standard‑of‑care antiretroviral therapy to a once‑weekly single‑tablet regimen of **islatravir‑lenacapavir** (islatravir 2 mg + lenacapavir 300 mg). - The study was randomised, open‑label, active‑controlled, non‑inferiority, conducted at 100 sites across 14 countries and territories. - Eligibility required adults (≥18 years) with HIV‑1, virologically suppressed on daily oral therapy for ≥6 months and no prior virological failure. - Participants were randomised 1:1 (stratified by region, antiretroviral class, and CD4+ count) to switch to once‑weekly islatravir‑lenacapavir or continue daily standard of care for at least 96 weeks; the primary analysis reported week 48 results. - Primary endpoint: proportion with HIV‑1 RNA ≥50 copies/mL at week 48 using the FDA Snapshot algorithm; non‑inferiority margin 4%, analyzed in all randomised participants who received any dose. - Enrollment and analysis numbers: 727 screened; 647 eligible; 634 randomised; 626 received treatment (314 islatravir‑lenacapavir, 312 standard‑of‑care). - Baseline demographics: 34% female, 31% Black, 19% Asian, 20% Hispanic/Latine, 14% aged ≥65 years; 88% were on a single‑tablet regimen and 76% on INSTI‑containing regimens at baseline. - Week 48 efficacy: 0.3% (1/314) in the islatravir‑lenacapavir arm and 1.3% (4/312) in the standard‑of‑care arm had HIV‑1 RNA ≥50 copies/mL; difference −1.0% (95.002% CI −3.0 to 1.1), meeting non‑inferiority. - Safety: treatment‑related adverse events reported in 18% of islatravir‑lenacapavir recipients versus <1% of standard‑of‑care recipients. Grade ≥3 adverse events occurred in 8% and 9% of participants respectively; serious adverse events in 7% and 9% respectively. Discontinuations for adverse events were 1% and <1%. Three deaths occurred (1 in islatravir‑lenacapavir, 2 in standard‑of‑care), none considered treatment‑related. - Interpretation: Once‑weekly **islatravir‑lenacapavir** demonstrated non‑inferior virological efficacy at week 48 and was generally well tolerated; longer‑term safety follow‑up is needed. - Trial registration: ClinicalTrials.gov NCT06630299. Funding from Gilead Sciences and Merck Sharp & Dohme.

### 13. [[177Lu]Lu-PSMA-617 for PSMA-positive metastatic androgen-pathway–sensitive prostate cancer (PSMAdd](https://medichelpline.com/clinical-feed/pubmed-42561994.md)
- **Source:** PubMed / NCBI | **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md) | **Published:** 2026-08-29 | DOI: [10.1016/S0140-6736(26)01092-5](https://doi.org/10.1016%2FS0140-6736(26)01092-5)
- **Read Full Markdown:** [[177Lu]Lu-PSMA-617 for PSMA-positive metastatic androgen-pathway–sensitive prostate cancer (PSMAdd](https://medichelpline.com/clinical-feed/pubmed-42561994.md)

> **Executive GIST:** - The article reports the PSMAddition phase 3, **randomised, controlled trial** evaluating **[177Lu]Lu-PSMA-617** in patients with **PSMA-positive metastatic androgen pathway modulator‑naive/sensitive prostate cancer**, as stated in the title. - The trial is named **PSMAddition** and enrolled patients described as PSMA‑positive with metastatic disease who were naive or sensitive to androgen pathway modulators, per the title. - Publication: Lancet; citation lists 2026 Aug 29;408(10557):793–807 with DOI 10.1016/S0140-6736(26)01092-5 and PubMed PMID 42561994. An Elsevier/Lancet full-text link is provided on PubMed. - Large, multi‑institutional and international author group is listed, including academic centers across North America, Europe, Asia, and authors affiliated with Novartis Pharmaceuticals, indicating a broad collaborative effort. - Lead and senior authors include Scott T Tagawa and Michael J Morris among many multinational investigators; full author list and institutional affiliations are reported on PubMed. - The PubMed entry identifies the study as a Clinical Trial and provides bibliographic and affiliation metadata; the abstract text, detailed methods, numerical results, safety data, and conclusions are not included in the provided source excerpt. - The PubMed record shows Epub 2026 Aug 6 and print date 2026 Aug 29; it lists DOI and PMID for reference and links to full-text options but does not present trial outcomes or statistical findings in the accessible excerpt. - Because the PubMed source excerpt lacks outcome, efficacy, safety, sample size, randomisation details, endpoints, and follow-up data, readers must consult the Lancet full text for trial methods and results.

### 14. [Centrally Acting Medications and Chronic Pain in Former American Football Players: Study Overview](https://medichelpline.com/clinical-feed/pubmed-42664488.md)
- **Source:** PubMed / NCBI | **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md) | **Published:** 2026-08-28 | DOI: [10.1212/WNL.0000000000218475](https://doi.org/10.1212%2FWNL.0000000000218475)
- **Read Full Markdown:** [Centrally Acting Medications and Chronic Pain in Former American Football Players: Study Overview](https://medichelpline.com/clinical-feed/pubmed-42664488.md)

> **Executive GIST:** - The source article titled **Centrally Acting Medications, Chronic Pain, and Orthopedic Surgical History Among Former American Football Players** is indexed in PubMed (PMID 42664488) and published in Neurology (2026 Sep 22;107[6]:e218475), DOI 10.1212/WNL.0000000000218475. - Authors are listed (Alexa Puleio et al.) with multiple institutional affiliations including Boston University, NYU Grossman School of Medicine, UC San Diego, Mayo Clinic, Cleveland Clinic, Concussion Legacy Foundation, Banner Alzheimer's Institute, Brigham and Women's Hospital, and others; the work is identified as from the DIAGNOSE CTE Research Project. - The title indicates the study focuses on the intersection of **centrally acting medications**, **chronic pain**, and **orthopedic surgical history** in a population of **former American football players**. - The PubMed entry includes bibliographic metadata (authors, affiliations, journal, publication date, PMID, DOI) but the abstract and study details (objectives, design, sample size, methods, results, conclusions) are not available in the provided source text. - Because the abstract/body text are not present in the source provided, specific findings, statistical results, medication classes evaluated, measures of chronic pain, and details of orthopedic surgical history were not reported and therefore cannot be summarized or interpreted here. - The available information allows accurate citation and identification of the article but does not permit extraction of clinical recommendations, efficacy or safety data, or study limitations beyond the lack of reported abstract content in this source. - Users should consult the full text of the article or the PubMed record with full abstract access for clinical details, data, and conclusions relevant to **pharmacologic management** and outcomes in this population.

### 15. [DTaP vaccination site and adverse reactions in children: upper arm versus buttock (Wuxi, 2020–2024)](https://medichelpline.com/clinical-feed/pubmed-42664027.md)
- **Source:** PubMed / NCBI | **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md) | **Published:** 2026-08-28 | DOI: [10.1080/21645515.2026.2723634](https://doi.org/10.1080%2F21645515.2026.2723634)
- **Read Full Markdown:** [DTaP vaccination site and adverse reactions in children: upper arm versus buttock (Wuxi, 2020–2024)](https://medichelpline.com/clinical-feed/pubmed-42664027.md)

> **Executive GIST:** - This retrospective observational study analyzed 636,169 **DTaP** inoculations in Wuxi, China, from 2020–2024 using provincial dose records and the National AEFI Surveillance System. - Investigators compared adverse reaction reporting rates by injection site: **upper arm** versus **buttock**, evaluating overall incidence, severity, dose-specific differences, and clinical manifestations. - Overall and common adverse reaction rates were higher after upper arm injection: 23.88 (95% CI 22.54–25.22) vs. 17.89 (95% CI 15.56–20.21) per 10,000 doses, and 23.13 (95% CI 21.81–24.45) vs. 16.94 (95% CI 14.68–19.20) per 10,000 doses, respectively (both p < .001). - Rates of rare reactions were similar between sites: 0.75 (95% CI 0.51–0.98) vs. 0.95 (95% CI 0.41–1.48) per 10,000 doses (p = .473). - Slightly elevated adverse reaction rates with upper arm administration were also observed for the first and second vaccine doses. - The most frequent clinical manifestations were **redness and swelling**, **induration**, and **fever**, each modestly more common after upper arm injection. - The majority of events at both injection sites were common reactions within expected ranges; rare reactions remained uncommon and comparable between sites. - Authors conclude that despite a small increase in common reaction reporting with upper arm injections, the upper arm may still be the preferred site for DTaP vaccination considering overall safety. - Keywords reported: diphtheria, tetanus, and acellular pertussis combined vaccine; adverse reaction; injection site; surveillance.

### 16. [FDA Approves Mimrylo (rusfertide) for Polycythemia Vera — First-in-Class Hepcidin Mimetic](https://medichelpline.com/clinical-feed/fda-news-releases-0-fda-approves-first-drug-of-its-kind-for-polycythemia-vera-a-rare-blood-disorder.md)
- **Source:** FDA News Releases | **Specialty:** [Hematology](https://medichelpline.com/clinical-feed/hematology.md) | **Published:** 2026-08-28
- **Read Full Markdown:** [FDA Approves Mimrylo (rusfertide) for Polycythemia Vera — First-in-Class Hepcidin Mimetic](https://medichelpline.com/clinical-feed/fda-news-releases-0-fda-approves-first-drug-of-its-kind-for-polycythemia-vera-a-rare-blood-disorder.md)

> **Executive GIST:** - The FDA approved Mimrylo (rusfertide) on August 28, 2026, for treatment of adults with **polycythemia vera**, a rare blood disorder characterized by excessive red blood cell production. - Mimrylo is described as a first-in-class therapy that **mimics hepcidin**, the hormone that regulates iron, thereby limiting iron availability for red blood cell synthesis. - The drug is intended for patients whose disease has not been adequately controlled with existing therapies and who require frequent phlebotomies. - Approval was based on the VERIFY phase 3 randomized, double-blind, placebo-controlled trial of 293 adults requiring frequent phlebotomies despite standard-of-care therapy. - In VERIFY, patients received subcutaneous Mimrylo starting at 19 mg once weekly with titration to maintain **hematocrit** below 45%. - The primary efficacy measure reported was the proportion of patients who did not meet criteria for phlebotomy between weeks 20 and 32. - Results showed 76.9% of Mimrylo-treated patients required no phlebotomy during the 32-week period versus 32.9% on placebo. - The most common adverse reactions in the trial were injection site reactions and anemia. - Mimrylo received priority review and the approval was granted to Takeda Pharmaceuticals America, Inc. - The FDA emphasized that maintaining hematocrit below 45% reduces cardiovascular risks associated with polycythemia vera, such as thrombosis, stroke, and heart attack. - The FDA noted that phlebotomy remains a common intervention but that some patients continue to require frequent procedures despite treatment; Mimrylo provides an alternative mechanism targeting iron regulation. - Additional specific safety, dosing titration details beyond those summarized in the release were not reported in the source.

### 17. [PML-driven sumoylation of PML::RARA-bound repressors and hematopoietic progenitor immortalization](https://medichelpline.com/clinical-feed/pubmed-42663568.md)
- **Source:** PubMed / NCBI | **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md) | **Published:** 2026-08-28 | DOI: [10.1084/jem.20252333](https://doi.org/10.1084%2Fjem.20252333)
- **Read Full Markdown:** [PML-driven sumoylation of PML::RARA-bound repressors and hematopoietic progenitor immortalization](https://medichelpline.com/clinical-feed/pubmed-42663568.md)

> **Executive GIST:** - This PubMed record (PMID 42663568, DOI 10.1084/jem.20252333) reports a 2026 J Exp Med article titled “PML-driven sumoylation of PML::RARA-bound repressors drives hematopoietic progenitor immortalization.” - The title indicates a mechanistic focus on **PML::RARA** fusion interactions, **sumoylation** driven by PML, and resulting **hematopoietic progenitor immortalization**, a process relevant to leukemogenesis. - The manuscript lists multiple contributing authors and French institutional affiliations including Collège de France, Université Paris-Cité, Sorbonne Université, and Assistance Publique–Hôpitaux de Paris; two authors contributed equally. - Publication metadata: J Exp Med, 2026 Sep 7;223(9):e20252333. Epub 2026 Aug 28. - The PubMed abstract in the provided source is truncated; the full abstract, experimental methods, results, and conclusions are not available in the supplied content. - Because the source body is incomplete, specific experimental approaches, key data, quantitative results, and precise mechanistic details beyond what the title states are not reported here. - The title implies relevance to acute promyelocytic leukemia (**APL**) biology given the PML::RARA fusion, but confirmation of disease context, model systems, or therapeutic implications is not reported in the provided text. - Readers should consult the full article (DOI 10.1084/jem.20252333) for complete data, methods, and conclusions; those elements were not present in the supplied source content.

### 18. [FDA clears Juul2 e‑cigarette with optional age‑verification feature](https://medichelpline.com/clinical-feed/stat-news-0-juul-gets-ok-to-sell-updated-vaping-device-with-age-gating-technology.md)
- **Source:** STAT News | **Specialty:** [General](https://medichelpline.com/clinical-feed/general.md) | **Published:** 2026-08-28
- **Read Full Markdown:** [FDA clears Juul2 e‑cigarette with optional age‑verification feature](https://medichelpline.com/clinical-feed/stat-news-0-juul-gets-ok-to-sell-updated-vaping-device-with-age-gating-technology.md)

> **Executive GIST:** - The Food and Drug Administration has authorized Juul Labs to market an updated version of its e‑cigarette device, which the company plans to sell as **Juul2**. The device includes an optional **age verification** system that can require users to authenticate via an online app before the device unlocks. - The FDA determination allows Juul to market updated tobacco‑ and menthol‑flavored cartridges and signals that smokers who switch completely to Juul products can reduce exposure to carcinogens and other harmful chemicals found in combustible cigarettes, according to the agency. - Juul presented company studies to the FDA showing that between **20% to 50%** of smokers who used Juul products were able to stop smoking by the end of six weeks; quit rates varied by flavor and nicotine strength. These study results were reviewed by the FDA as part of its decision. - The agency emphasized the authorization is not an approval or endorsement and stated that people who do not smoke should not use Juul or any other e‑cigarette. - Juul has faced major legal and financial consequences in recent years: it has laid off hundreds of employees and paid roughly **$3 billion** to settle government and private lawsuits related to teen use of its products. - In 2019 Juul discontinued several flavors, including mango, mint and creme, flavors that previously drove much of its sales and were reported to be favored by teens. - Juul’s CEO K.C. Croswaite said the company will market the new system with “a portfolio of flavors — beyond tobacco and menthol — that are targeted to adult nicotine consumers.” - Juul is no longer the top‑selling e‑cigarette brand in the U.S.; it trails **Vuse**, sold by Reynolds American. Federal figures show teen vaping has declined and that the teens who continue to vape mostly use unauthorized disposable e‑cigarettes imported from China that come in fruit and candy flavors. - The FDA has previously authorized several e‑cigarette products intended to help adult smokers quit or reduce cigarette use, and recent regulatory actions include the authorization of the first fruit‑flavored electronic cigarettes intended for adult smokers. - The article is sourced from the Associated Press and notes the AP Health and Science Department’s funding acknowledgments; the AP is responsible for the reported content.

### 19. [How the Lindsay Clancy Case May Reduce Access to Postpartum Psychiatric Care](https://medichelpline.com/clinical-feed/stat-news-1-opinion-the-unintended-consequences-of-the-lindsay-clancy-case.md)
- **Source:** STAT News | **Specialty:** [General](https://medichelpline.com/clinical-feed/general.md) | **Published:** 2026-08-28
- **Read Full Markdown:** [How the Lindsay Clancy Case May Reduce Access to Postpartum Psychiatric Care](https://medichelpline.com/clinical-feed/stat-news-1-opinion-the-unintended-consequences-of-the-lindsay-clancy-case.md)

> **Executive GIST:** - Authors Renee Sorrentino and Susan Hatters Friedman, both forensic psychiatrists with leadership roles in the American Academy of Psychiatry and the Law, argue that legal and media scrutiny of the Lindsay Clancy case could have damaging unintended consequences for maternal mental health care. - The Clancy case — a criminal trial now before a jury involving the mother who killed her three children — has focused attention on alleged clinical failures in diagnosing and treating perinatal psychiatric illness. - There are only about **500 reproductive psychiatrists** practicing in the United States, so general psychiatrists and OB-GYNs often serve as frontline providers for perinatal mental health disorders. - The authors are concerned that heightened liability concerns could lead general psychiatrists to avoid treating mothers with psychiatric symptoms or to practice defensive medicine. - Specific areas of scrutiny in the case include alleged missed diagnoses, questions about the adequacy of **telehealth**, and medication management decisions; these critiques may stigmatize virtual visits and common treatment choices. - Defensive responses could include unnecessary hospitalization for perinatal symptoms (including intrusive thoughts and depressive symptoms that typically do not require inpatient care), increased separation of mothers from infants, and more referrals to child protective services — all of which could deter mothers from reporting symptoms or seeking care. - The authors recommend education and awareness rather than fear-driven avoidance; they note efforts by reproductive psychiatrists to address training gaps, including the **National Curriculum in Reproductive Psychiatry** and an AAPL practice resource on forensic reproductive psychiatry. - The article emphasizes that the right response is to expand knowledge and support for clinicians treating maternal mental illness rather than fostering an environment of avoidance and defensive practice.

### 20. [EMTALA Overview: Clinical and Ethical Implications for Pediatric Emergency Care](https://medichelpline.com/clinical-feed/pubmed-42661262.md)
- **Source:** PubMed / NCBI | **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md) | **Published:** 2026-08-28 | DOI: [10.1097/PEC.0000000000003591](https://doi.org/10.1097%2FPEC.0000000000003591)
- **Read Full Markdown:** [EMTALA Overview: Clinical and Ethical Implications for Pediatric Emergency Care](https://medichelpline.com/clinical-feed/pubmed-42661262.md)

> **Executive GIST:** - The Emergency Medical Treatment and Active Labor Act (**EMTALA**) was enacted in 1986 to ensure access to emergency medical care after widespread patient dumping of uninsured patients. - The law applies to Medicare-participating hospitals that have dedicated emergency departments and imposes three core obligations: provide an appropriate **medical screening examination**, stabilize **emergency medical conditions**, and facilitate appropriate transfers when necessary. - Over roughly four decades, amendments and regulatory clarifications have expanded EMTALA's scope and strengthened enforcement mechanisms. - Pediatric practice raises distinct considerations, including a **reverse dumping** provision that requires hospitals with specialized pediatric capabilities to accept appropriate transfers when capacity exists. - EMTALA includes standards for pediatric transport during interfacility transfers; these standards aim to protect children during transfer processes. - The statute's narrow focus on emergency care creates ethical questions about whether this minimum standard sufficiently addresses broader child health needs beyond immediate stabilization. - Understanding EMTALA's requirements, limitations, and pediatric-specific provisions is essential for pediatric emergency clinicians who must balance clinical, legal, and ethical obligations in contemporary practice. - Keywords highlighted in the source include Emergency Medical Treatment and Labor Act, ethical dimensions of EMTALA, and pediatric emergency care and transfer obligations.

### 21. [ENDO 2026: Progress and Resilience in Endocrinology and Obesity Care](https://medichelpline.com/clinical-feed/endocrine-news-0-endo-2026-progress-and-resilience.md)
- **Source:** Endocrine News | **Specialty:** [Endocrinology](https://medichelpline.com/clinical-feed/endocrinology.md) | **Published:** 2026-08-28
- **Read Full Markdown:** [ENDO 2026: Progress and Resilience in Endocrinology and Obesity Care](https://medichelpline.com/clinical-feed/endocrine-news-0-endo-2026-progress-and-resilience.md)

> **Executive GIST:** - ENDO 2026, held in Chicago in June, showcased the field’s resilience amid funding and healthcare uncertainties and highlighted continuing advances in **endocrinology**. - A central theme was the expanding role of **GLP-1** medications: originally for diabetes, now approved and increasingly used for **obesity** treatment, but not a complete solution and requiring continued lifestyle and environmental interventions. - Daniel Drucker and Barbara Kahn emphasized the need to address environmental and food-system drivers of rising BMI and predicted that by 2036 either prevention will obviate widespread drug use or many affordable GLP-1 options will exist. - Affordability and access remain major barriers: semaglutide costs about $78 Canadian for a month in Canada; disparities exist by race/ethnicity and insurance status for bariatric surgery and new obesity medications. - Sessions addressed health equity: Black, Hispanic and Asian patients are less likely to use new obesity medications, and speakers urged recognizing obesity as a disease and confronting weight bias and systemic barriers. - New research presented included a collaborative tirzepatide analysis of about **80,000** adults showing greater weight loss in women and reduced response among people with several comorbidities (type 2 diabetes, dyslipidemia, hypertension, metabolic liver disease, obstructive sleep apnea). - Chinese researchers linked daily naps longer than 30 minutes in people with type 2 diabetes to higher risk of metabolic dysfunction-associated steatotic liver disease, prompting the message to “nap wisely.” - An industry-sponsored study of the nonhormonal menopausal treatment **fezolinetant** reported improvements in hot flashes, depression and anxiety, and results mirrored clinical trial findings in a broader population. - Overall, presenters stressed that GLP-1s and related agents are transformative for many patients but must be paired with efforts on environment, prevention, access and individualized care.

### 22. [ADHD Stimulant Use in Pregnancy: Study Links Continued Exposure to Higher Maternal and Fetal Risks](https://medichelpline.com/clinical-feed/womens-mental-health-0-adhd-stimulants-and-pregnancy-new-study-examines-risks-of-continued-treatment.md)
- **Source:** Women's Mental Health | **Specialty:** [General](https://medichelpline.com/clinical-feed/general.md) | **Published:** 2026-08-28
- **Read Full Markdown:** [ADHD Stimulant Use in Pregnancy: Study Links Continued Exposure to Higher Maternal and Fetal Risks](https://medichelpline.com/clinical-feed/womens-mental-health-0-adhd-stimulants-and-pregnancy-new-study-examines-risks-of-continued-treatment.md)

> **Executive GIST:** - A large claims-based study of 24,200 pregnancies with prescription **stimulant** exposure using MarketScan data (2013–2021) compared exposed pregnancies to matched unexposed controls. - Of the exposed group, 25.3% had exposure before conception only; 74.7% had exposure during pregnancy. Among those exposed during pregnancy, 56.8% discontinued in the first trimester and 43.2% continued into the second or third trimester. - First-trimester-only stimulant exposure was not associated with increased risk for most adverse outcomes and was linked to lower rates of spontaneous abortion, **preterm birth**, and **small-for-gestational-age** infants compared with unexposed pregnancies. - Continued stimulant exposure into trimesters 2 and 3 was associated with higher rates of hypertensive disorders, **pre-eclampsia**, **placental abruption**, **preterm birth**, **stillbirth**, and **small-for-gestational-age** infants compared with both unexposed pregnancies and pregnancies with first-trimester-only exposure. - Relative risks reported for continuation versus first-trimester-only exposure included: **pre-eclampsia** RR 1.33 (95% CI 1.12–1.59); **placental abruption** RR 1.78 (95% CI 1.11–2.84); **stillbirth** RR 3.54 (95% CI 1.48–8.44); **preterm birth** RR 1.86 (95% CI 1.51–2.28); **small for gestational age** RR 1.47 (95% CI 1.12–1.92). Gestational hypertension showed no significant difference between groups. - Authors propose biological plausibility: stimulants can raise blood pressure and cause vasoconstriction, potentially reducing placental perfusion and contributing to adverse obstetric outcomes. - The study is observational and used propensity-score matching, so **confounding by indication** and unmeasured factors (ADHD severity, stimulant dose, psychiatric comorbidity, health behaviors, prenatal care engagement) may explain some associations; causation is not established. - Clinical implication: decisions about continuing or stopping stimulant treatment during pregnancy should be individualized, balancing potential medication-related risks against risks of untreated ADHD, including impaired functioning and vulnerability to perinatal mood and anxiety disorders. - The report is part one of a three-part series reviewing ADHD medication use in pregnancy and cites Hasan et al., J Atten Disord. 2026;30(3):315–328 as the primary study source.

### 23. [Meteorological drivers of childhood diarrhea in Tanzania: seasonal patterns and short-term associa](https://medichelpline.com/clinical-feed/plos-one-9-seasonal-trends-and-short-term-association-between-meteorological-factors-and.md)
- **Source:** PLOS ONE (Medicine) | **Specialty:** [Pediatrics](https://medichelpline.com/clinical-feed/pediatrics.md) | **Published:** 2026-08-28
- **Read Full Markdown:** [Meteorological drivers of childhood diarrhea in Tanzania: seasonal patterns and short-term associa](https://medichelpline.com/clinical-feed/plos-one-9-seasonal-trends-and-short-term-association-between-meteorological-factors-and.md)

> **Executive GIST:** - Childhood **diarrhea** remains a leading cause of morbidity and mortality in Tanzanian children under five and is climate-sensitive, with transmission influenced by temperature, rainfall and humidity. - This study analysed routine surveillance data from 10 healthcare facilities across seven Tanzanian regions between 1 May 2023 and 30 April 2024, linking health records with meteorological data from the Tanzania Meteorological Authority. - A total of 898 children under five were included; median age was 13.9 months (IQR 8.8–25.3 months). - Seasonal prevalence differed by regional rainfall regime: in **unimodal** rainfall regions the highest prevalence occurred in the dry season (58%), while in **bimodal** regions prevalence peaked in the wet season (41%). - Multilevel mixed-effects **Poisson regression** with robust standard errors was used to estimate short-term associations between meteorological factors and diarrheal prevalence. - Higher average monthly **temperature** and greater total monthly **rainfall** were significantly associated with higher prevalence of childhood diarrhea across both rainfall-pattern regions. - Younger child age and maternal primary education were additional sociodemographic factors associated with higher diarrheal prevalence in the final model. - The authors conclude that integrating meteorological information into diarrheal surveillance and public health planning could support timely interventions to reduce childhood diarrhea. - Data were drawn from the Seq-Tanzania project and stored in **DHIS2**; de-identified data access requires approval from the Seq-Tanzania project and KCRI. Funding was provided by DANIDA via the Seq-Tanzania project. - Details not reported in the source excerpt: full description of data linkage procedures, specific meteorological variables beyond monthly temperature and rainfall, model coefficients and effect sizes, and detailed ethical approval information were not provided in the available text.

### 24. [Labeling strategy shapes machine learning detection of visual field progression in glaucoma](https://medichelpline.com/clinical-feed/plos-one-8-labeling-matters-a-multicenter-machine-learning-study-on-visual-field.md)
- **Source:** PLOS ONE (Medicine) | **Specialty:** [General](https://medichelpline.com/clinical-feed/general.md) | **Published:** 2026-08-28
- **Read Full Markdown:** [Labeling strategy shapes machine learning detection of visual field progression in glaucoma](https://medichelpline.com/clinical-feed/plos-one-8-labeling-matters-a-multicenter-machine-learning-study-on-visual-field.md)

> **Executive GIST:** - This multicenter retrospective study compared how two algorithm-derived labeling strategies affect machine learning (ML) performance for detecting **visual field** (VF) progression in **glaucoma** using data from five tertiary hospitals. - Two labeling approaches were evaluated without an independent clinical reference: an inclusive **Consensus label** (progression if at least one of five conventional algorithms flagged it) and a conservative **Wiggs’ label** (region-based event–threshold rule). - Five conventional progression algorithms contributed to the Consensus definition: MD slope, VFI slope, AGIS, CIGTS, and pointwise linear regression (PLR). - Four ML classifiers were trained separately with each label: support vector machine (SVM), random forest (RF), logistic regression (LR), and extreme gradient boosting (XGBoost). - Performance metrics included area under the ROC curve (AUC), sensitivity, specificity, precision–recall analysis summarized by average precision (AP). - Models trained with the Consensus label achieved excellent discrimination (AUC 0.92–0.95), high sensitivity (0.82–0.85), near-perfect specificity (0.99–1.00), and high AP (0.93–0.94). - Models trained with the Wiggs’ label showed lower discrimination (AUC 0.88–0.89), reduced sensitivity (0.63–0.72), moderate-to-high specificity (0.87–0.92), and lower AP (0.84–0.85), reflecting a stricter spatial requirement for progression. - Ablation analysis suggested Consensus-based performance relied on complementary information across heterogeneous algorithms rather than on any single criterion. - The authors conclude that labeling strategy is a major determinant of ML performance for VF progression detection and that model performance largely reflects compatibility with the chosen ground truth rather than validating one clinical standard over another. - The study underscores the need for careful ground-truth definition when developing and interpreting ML models for glaucoma progression research.

### 25. [FDMB-YOLOv11: Robust traffic police gesture recognition across lighting conditions](https://medichelpline.com/clinical-feed/plos-one-6-fdmb-yolov11-traffic-police-command-gesture-recognition-method-under-different.md)
- **Source:** PLOS ONE (Medicine) | **Specialty:** [General](https://medichelpline.com/clinical-feed/general.md) | **Published:** 2026-08-28
- **Read Full Markdown:** [FDMB-YOLOv11: Robust traffic police gesture recognition across lighting conditions](https://medichelpline.com/clinical-feed/plos-one-6-fdmb-yolov11-traffic-police-command-gesture-recognition-method-under-different.md)

> **Executive GIST:** - The paper introduces **FDMB-YOLOv11**, a lightweight object detection model based on the YOLOv11n architecture, aimed at real-time recognition of Chinese traffic police command gestures under varying lighting conditions. - Key architectural changes include adding **Frequency Adaptive Dilated Convolution (FADC)** to the detection head, integrating the **BiFormer** attention mechanism into the C2PSA module, replacing standard convolutions with **Deformable Convolution**, and adopting **MobileNetV4** as the backbone to reduce compute and parameters. - The model targets eight standardized Chinese traffic police gestures used for single-image detection: Stop, Go straight, Turn right, Turn left, Wait for the left turn, Slow down, Lane change, and Pull over. - On normal lighting conditions FDMB-YOLOv11 achieved precision 97.91%, recall 93.32%, and **mAP@0.5** 97.17%, representing improvements of 23.1%, 13.63%, and 16.74% respectively over the YOLOv11n baseline reported in the paper. - Model size was reduced from 2.58 million parameters (YOLOv11n) to 1.93 million parameters, indicating a successful lightweight optimization while maintaining real-time inference; reported FPS is 65.789. - The paper reports that FDMB-YOLOv11 outperformed SSD, Faster R-CNN, RTDETR, YOLOv12, and YOLOv13 on mAP@0.5 in the authors’ experiments and specifically addressed misclassification between left-turn and right-turn gestures seen in YOLOv11n. - Dataset resources used include the publicly available ChineseTrafficPolicePose dataset; data processing and augmentation code archived on Zenodo (DOI provided in the source). - The authors note the practical trade-offs in on-board deployment: extreme lighting, limited hardware compute, and the need to balance accuracy, robustness, and model complexity. Funding sources and conflict-of-interest statements are provided in the article.

### 26. [Acetylation-related biomarkers in osteoarthritis: bioinformatics identification of JUN and MYC](https://medichelpline.com/clinical-feed/plos-one-5-exploration-of-acetylation-related-biomarkers-in-osteoarthritis-through.md)
- **Source:** PLOS ONE (Medicine) | **Specialty:** [Rheumatology](https://medichelpline.com/clinical-feed/rheumatology.md) | **Published:** 2026-08-28
- **Read Full Markdown:** [Acetylation-related biomarkers in osteoarthritis: bioinformatics identification of JUN and MYC](https://medichelpline.com/clinical-feed/plos-one-5-exploration-of-acetylation-related-biomarkers-in-osteoarthritis-through.md)

> **Executive GIST:** - Osteoarthritis (OA) is a chronic degenerative joint disease with limited disease-modifying treatments; identification of biomarkers could improve diagnosis and therapy. - The study integrated synovial membrane microarray datasets GSE55235, GSE55457, and GSE12021 as a training cohort (29 OA, 29 controls) and used GSE82107 as a validation cohort (10 OA, 7 controls). - A list of **4,405 acetylation-related genes** was extracted from GeneCards using a relevance score cutoff > 2. - Differentially expressed genes (DEGs) were identified with |log2FC| > 0.5 and p < 0.05 using the limma package; functional enrichment (GO/KEGG) was performed on DEGs. - Weighted gene co-expression network analysis (**WGCNA**) was conducted with a soft threshold of 14, yielding five merged modules; the red module was selected as the core OA-associated module. - Intersection of core module genes, acetylation-related genes, and DEGs produced acetylation-related DEGs (ACEDEGs); a protein–protein interaction (PPI) network was built via STRING and analyzed in Cytoscape, with top genes prioritized by the MCC algorithm. - Three machine learning approaches (LASSO, Random Forest, XGBoost) were applied to refine hub gene selection. - A diagnostic prediction model (nomogram) was constructed and evaluated: training AUC = **0.983**, validation AUC = **0.743**. - Immune cell infiltration analyses using CIBERSORT revealed significant alterations in immune cell composition between OA and controls. - Experimental validation by qRT-PCR and Western blot confirmed down-regulation of **JUN** and **MYC** in OA synovial samples. - The study proposes **JUN** and **MYC** as novel acetylation-related biomarkers for OA and suggests potential roles in OA pathophysiology and diagnostics.

### 27. [Optimizing Traffic Police Service Districts and Patrol Routes to Enhance Urban Road System Resilie](https://medichelpline.com/clinical-feed/plos-one-4-resilience-enhancement-oriented-traffic-police-service-district-division-and.md)
- **Source:** PLOS ONE (Medicine) | **Specialty:** [General](https://medichelpline.com/clinical-feed/general.md) | **Published:** 2026-08-28
- **Read Full Markdown:** [Optimizing Traffic Police Service Districts and Patrol Routes to Enhance Urban Road System Resilie](https://medichelpline.com/clinical-feed/plos-one-4-resilience-enhancement-oriented-traffic-police-service-district-division-and.md)

> **Executive GIST:** - This study develops a **bi-level programming model** to jointly optimize traffic police service district division and patrol route planning (TPSD-PR) with the explicit goal of enhancing urban road system **resilience**. - The upper level partitions the jurisdiction into contiguous, compact service districts under limited patrol teams (PTs); the lower level designs patrol routes within those districts. - A hybrid solution algorithm combining the non-dominated sorting genetic algorithm II (**NSGA-II**) and **simulated annealing (SA)** is proposed to solve the bi-level model. - Case studies on a real-world urban road system demonstrate reductions in total weighted patrol time (2.01%) and workload variance across teams (17.92%) compared with the current scheme. - Increasing the number of patrol teams improved objective values but reduced solution efficiency; historical accident severity directly affected objectives, indicating its importance in scheme design. - The model assumes PTs follow shortest paths between basic areas (BAs), ignores the influence of suddenly occurring accidents on scheme design, and links patrol time at a BA to accident severity (assumptions A1–A3). - Literature gaps motivating the study include limited cooperative optimization of district division and patrol routing, insufficient incorporation of historical accident data, and scarce resilience-oriented models for traffic police operations. - The paper includes a review of district division methods (P-center, P-median, covering models) and patrol routing approaches (single- and multi-objective), and positions the current work as a resilience-focused, cooperative optimization contribution. - Practical implications and parameter sensitivity analyses are reported; several operational suggestions are proposed to improve urban road resilience during traffic events.

### 28. [Sarcocystis neurona genotypes in California sea lions with polyphasic rhabdomyositis](https://medichelpline.com/clinical-feed/plos-one-3-molecular-characterization-of-sarcocystis-neurona-genotypes-in-california-sea.md)
- **Source:** PLOS ONE (Medicine) | **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md) | **Published:** 2026-08-28
- **Read Full Markdown:** [Sarcocystis neurona genotypes in California sea lions with polyphasic rhabdomyositis](https://medichelpline.com/clinical-feed/plos-one-3-molecular-characterization-of-sarcocystis-neurona-genotypes-in-california-sea.md)

> **Executive GIST:** - A syndrome of **polyphasic rhabdomyositis** associated with **Sarcocystis neurona** has been described in free-ranging California sea lions (CSLs); its pathogenesis remains poorly understood. - This study screened archived skeletal muscle from 25 CSLs with moderate to severe S. neurona–associated rhabdomyositis for parasite DNA and performed multilocus sequence typing (MLST). - DNA screening used a nested PCR targeting the multi-copy **ITS1** locus to confirm S. neurona, followed by MLST across six polymorphic loci (SnSAG1/5/6, SnSAG3, SnSAG4, sn3, sn7, sn9). - From 25 cases, investigators identified 15 distinct **S. neurona genotypes**; six matched genotypes previously reported in other hosts and nine were novel to date. - The most frequently detected genotypes were **IIg/j** (6/25, 24%), **Ib/c/d/gg** (3/25, 12%), **IIi** (2/25, 8%), **IIIl/m/o** (2/25, 8%), and **VIIr** (2/25, 8%). - One new surface antigen type (XV) and five new microsatellite types (nn, oo, pp, qq, rr) were reported. - Genotypes previously implicated in severe disease in other marine mammals (e.g., Ia, Ib/c/d/gg, IIg/j, IIi, VIy, IIIl/m/o) were present among CSLs, but many genotypes were unique to CSLs in this sample. - The geographic sampling spanned a ~450-km central California coastline (San Francisco to Morro Bay); cases were collected randomly (2–4 animals/year) from 2017–2024 and were animals that died or were euthanized during care. - Authors conclude the high genotype diversity in a small sample suggests parasite genotype alone may not drive the CSL rhabdomyositis syndrome and support a potential host-driven or immune-mediated mechanism. - Study limitations include small sample size, potential under-detection of mixed infections with MLST, and that archived samples were used rather than prospectively collected material.

### 29. [Cropland type determines arbuscular mycorrhizal fungi (AMF) density and diversity in Northwest Eth](https://medichelpline.com/clinical-feed/plos-one-23-cropland-type-shapes-arbuscular-mycorrhizal-fungi-amf-population-density-and.md)
- **Source:** PLOS ONE (Medicine) | **Specialty:** [General](https://medichelpline.com/clinical-feed/general.md) | **Published:** 2026-08-28
- **Read Full Markdown:** [Cropland type determines arbuscular mycorrhizal fungi (AMF) density and diversity in Northwest Eth](https://medichelpline.com/clinical-feed/plos-one-23-cropland-type-shapes-arbuscular-mycorrhizal-fungi-amf-population-density-and.md)

> **Executive GIST:** - This study assessed how farm and soil fertility management affect **arbuscular mycorrhizal fungi (AMF)** population density, species diversity and richness in teff (Eragrostis tef) and maize (Zea mays) croplands in three districts of East Gojjam Zone, Northwest Ethiopia. - Field sampling covered three districts (Aneded, Awabel, Gozamin) at 2350–2500 m elevation with average annual rainfall ~1380 mm; samples were collected during the 2023 dry season (October–December). - A total of 14 croplands were sampled (7 teff, 7 maize). At each farmland five subsamples (N, S, E, W, Center) were combined to produce a composite sample; nearby uncultivated plots served as controls. - Soil handling: 1 kg composite samples were split into two 500 g subsamples for AMF spore extraction and soil parameter analysis; analyses were performed at Debre Markos University and Addis Ababa University laboratories. - AMF spores were extracted, quantified and morphologically identified. Results showed significant variation (p < 0.05) in average spore counts by district, by sampling location and by crop type. - Controls had higher average spore density (63.33 spores per 100 g dry soil) than croplands (47.59 spores per 100 g dry soil), supporting the hypothesis that cultivation and soil management reduce AMF abundance. - Maize croplands had higher AMF spore densities (up to 112.67 spores per 100 g dry soil) and a higher average AMF density (66 spores per 100 g dry soil) than teff croplands (30 spores per 100 g dry soil). - Fourteen AMF morphotypes were identified, representing three genera; **Acaulospora** and **Pacispora** were dominant. Dominant species included Acaulospora myricarpa and Pacispora franciscana. - The authors conclude that farm and soil fertility management practices decreased AMF population density and species diversity and recommend maintaining AMF diversity to support soil health and sustainable crop productivity in the context of climate change. - Study metadata: open access PLoS ONE research article; data are included in the manuscript; no specific funding declared; ethical approval and informed consent were obtained.

### 30. [Enteric pathogens causing diarrhoea in rotavirus‑vaccinated Ghanaian children under five](https://medichelpline.com/clinical-feed/plos-one-22-enteric-pathogens-in-children-under-five-with-diarrhoea-in-a-rotavirus.md)
- **Source:** PLOS ONE (Medicine) | **Specialty:** [Pediatrics](https://medichelpline.com/clinical-feed/pediatrics.md) | **Published:** 2026-08-28
- **Read Full Markdown:** [Enteric pathogens causing diarrhoea in rotavirus‑vaccinated Ghanaian children under five](https://medichelpline.com/clinical-feed/plos-one-22-enteric-pathogens-in-children-under-five-with-diarrhoea-in-a-rotavirus.md)

> **Executive GIST:** - Study setting: cross-sectional facility-based assessment in the Anloga district, a coastal district in the Volta region of Ghana, conducted November 2022–August 2023. The population was children under five presenting with diarrhoea. - Objective: determine diarrhoea etiologies and severity in a population with high **rotavirus** vaccine coverage to identify prevailing enteric pathogens and co-infection patterns. - Sampling and laboratory testing: the paper reports a calculated sample size of 83 for rotavirus A testing; a subset was selected for molecular analysis. Stool specimens were tested by ELISA for rotavirus antigen and by TAQMAN Array Card RT‑PCR for multiple pathogens; standard sample collection and cold‑chain transport procedures were used. - Demographics and clinical severity: the reported median age was 21.5 months (IQR 12–30); 55.3% male. About half of cases were classified as moderate severity using the Vesikari Clinical Severity Scoring System. - Key pathogen prevalence reported: **Enteroaggregative Escherichia coli (EAEC)** (52.6%), **Shigella/Enteroinvasive E. coli (Shigella/EIEC)** (76.3%), **Norovirus** (26.3%), and **Giardia** as the main identified parasite. **Rotavirus A** prevalence was low (2.5%). - Co-infection: very high co-infection rate reported (94.7%). Bacteria–virus co-infections were associated with higher proportions of moderate to severe diarrhoea (reported 73.3% of such co-infections). Norovirus was present in most severe cases (reported 75% of severe cases). - Conclusions and implications: predominant pathogens were EAEC, Shigella/EIEC and Norovirus in this rotavirus‑vaccinated population. High rates of co-infection—especially bacteria–virus combinations—were linked to greater severity. The authors recommend periodic pathogen surveillance and strengthened water, sanitation and hygiene (**WASH**) measures; the source also recommends collaboration with national research institutions for ongoing monitoring. - Notes on reporting: the article provides multiple sample counts across sections (sample size calculation, rotavirus testing cohort, and molecular subset). Specific methodological details (for example, exact numbers tested by each method and full lab protocol steps) are described in the source; any apparent differences in sample counts are those recorded in the paper.


## Navigation & Machine-Readable Pagination
- [Next Page (Page 2) →](https://medichelpline.com/clinical-feed.md?page=2)
- [Full AEO Knowledge Feed (JSON)](https://medichelpline.com/api/seo/aeo-geo)
- [AEO Guidelines & Platform Context](https://medichelpline.com/llms.txt)

## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.